Seasonal variations in the eight time series between summer and winter.

#<p>expressed as number of boxes per week per 100,000 inhabitants.</p>*<p>Google searches containing the terms cystitis and/or urinary tract infection. Each is rescaled between 0 and 100 by Google Trends internal processes at download.</p><p>sd = standard deviation.</p

Time series of antibiotic sales and Google search queries for urinary tract infections.

<p>Using “fosfomycin and sulfamethazole” for antibiotic sales, 2000–2012, in France and “cystitis or urinary tract infection” for Google search queries, 2004–2012 in France, the USA, Brazil, Italy, Germany, China and Australia indicated in grey. Black lines show the model's predictions. The horizontal axis represents the time of year, the vertical axis for antibiotic sales represents drug sales (in number of boxes per 100,000 inhabitants), and the vertical axis for Google search queries represents search fraction. Search fractions are rescaled between 0 and 100 by Google Trends internal processes at download.</p

Relative Illness Ratio by age-group for the 2011/2012 epidemic (solid line) and mean of cumulated age-specific incidence by viral dominant or co-dominant subtypes for others epidemics from 1999–2000 epidemic (dashed lines).

<p>A(H1N1) and co-dominant A(H1N1),B before 2009 pandemic are grouped together). The number of epidemic included in each group is indicated between parentheses in the legend.</p

Vaccine effectiveness of people of 15–64 y and 65 and over, of the epidemics between 1999 and 2011 (in percent) and mismatch between dominant or co-dominant circulating strains and vaccine strains.

<p>^a Because vaccine effectiveness (VE) for 2009–2010 and 2010–2011 epidemics were estimated using different vaccination coverage sources (administrative source <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0065919#pone.0065919-Vaux1" target="_blank">[44]</a> and from GPs practices respectively) and strata (week for 2009–2010 and risk-group for influenza for 2010–2011 epidemic) we did not shown these VE estimated values in this study. ^b Indicate the viral dominant type or subtype when it differs from the vaccine strain for the season. Only mismatch with dominant type is considered. ‘–‘ indicate the circulating strains were close to the vaccine’s ones. ^c One of the 2 circulating A(H3N2) strains differed from the vaccine one.</p

Effectiveness of trivalent seasonal influenza vaccine, for each epidemic, by age-group (15–64 year-old, over 65 year-old and overall) estimated by the French <i>Sentinelles</i> Network.

<p>Colors and types of point indicate the dominant or co-dominant viral subtype for each epidemic. Segments delimitate the 95% confidence intervals of the point estimates (circles or squared dots). Epidemic seasons are indicated above each estimation. Epidemics 2009–2010 and 2010–2011 are not shown.</p

Cumulated incidence rates and corresponding 95% confidence intervals of influenza-like illness per 100,000 inhabitants by age-group for epidemic seasons between 1999 and 2011.

<p>Cumulated incidence rates and corresponding 95% confidence intervals of influenza-like illness per 100,000 inhabitants by age-group for epidemic seasons between 1999 and 2011.</p

Circulating viruses in France by epidemic (from FluNet database).

a<p>Proportion corrected to include not subtyped A viruses^b Data for the 2008–2009 are from Grog network only.^c A majority of type B was circulating in general practice. A(H1N1) was mostly reported from hospital based tests during the 2002–2003 season.</p

Seasonal vaccine uptake among laboratory-confirmed cases included in the seasonal vaccine effectiveness analysis.

<p>Seasonal vaccine uptake among laboratory-confirmed cases included in the seasonal vaccine effectiveness analysis.</p

Field effectiveness of seasonal vaccines, by case definition, age group and study period.

<p>Field effectiveness of seasonal vaccines, by case definition, age group and study period.</p

Pandemic vaccine uptake among laboratory-confirmed cases included in the pandemic vaccine effectiveness analysis.

<p>Pandemic vaccine uptake among laboratory-confirmed cases included in the pandemic vaccine effectiveness analysis.</p